The prestigious Fierce 15 biotech award has come to symbolize novelty and being at the forefront of biotechnology development amongst privately held businesses. The winners of this award are aiming at breakthroughs and big things, not at being 'me-too'. This unique product, the 'Fierce 15 in Oncology Drug Pipeline Update' gathers the last six years (2010-2015) of Fierce 15 awards and identifies that no less than 54 of these biotech companies who are developing cancer drugs. This is a solid 60% of all companies given the award. Fierce 15 companies are fast movers and to date no less than seventeen out of the 54 companies are public companies and four have been acquired, namely Amira Pharmaceuticals, Aragon Pharmaceuticals, Avila Therapeutics and Plexxikon. FibroGen is the oldest among them, founded in 1993, otherwise all others are from the beginning of 2000 to present day. Among the very latest of the start-ups you will find Surface Oncology, Intellia Therapeutics, CRISPR Therapeutics, SQZ Biotech and Unum Therapeutics. Available for the first time, Fierce 15 in Oncology lets you perform detailed pipeline analysis on their collective and very impressive pipeline of more than 290 drugs, spanning from Discovery to Marketed and in-house to co-development/in-licensing. Twenty eight drugs have one or more orphan drug designations and six drugs have received breakthrough therapy designation. Key technologies among this group of companies include CAR-T, TCRs, Immuno-oncology, Immune checkpoints, Gene editing etc. There are today 72 companies plus partners developing 201 Fierce 15 drugs in 600 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 34 drugs. Fierce 15 In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 130 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 121 out of the 124 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 39 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Investigators Includes more than 72 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 201 Fierce 15 drugs in development, which have a total of 600 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs Marketed# 4 Pre-registration# 1 Phase III# 9 Phase II# 39 Phase I# 60 Preclinical# 91 No Data# 3 Suspended# 2 Ceased# 34
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included Fierce 15 drugs are also in development for 129 other indications, where of 102 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 121 out of the 124 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
Biological Structures The identity of available biological structures on 95 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 1407 structures available today among drug targets.
Identified drugs are linked to more than 130 different targets, divided into 39 classifications of molecular function: Antigen binding ATPase activity Auxiliary transport protein activity Catalytic activity Cell adhesion molecule activity Cytokine activity
DNA binding DNA topoisomerase activity Extracellular matrix structural constituent G-protein coupled receptor activity Growth factor activity GTPase activity Helicase activity Kinase activity Ligand-dependent nuclear receptor activity Ligase activity Lipid kinase activity Metallopeptidase activity Methyltransferase activity MHC class I receptor activity Molecular function unknown Protein binding Protein serine/threonine kinase activity Protein-tyrosine kinase activity Receptor activity Receptor binding Receptor signaling complex scaffold activity Receptor signaling protein serine/threonine kinase activity Structural constituent of cytoskeleton Sugar-phosphatase activity T cell receptor binding Transcription factor activity Transcription regulator activity Transferase activity Translation regulator activity Transmembrane receptor activity Transmembrane receptor protein tyrosine kinase activity Transporter activity Ubiquitin-specific protease activity
Sub-Cellular Localization Identified targets are categorized into 21 different primary and alternate sub-cellular localizations: Basolateral membrane Cell junction Cell surface Centrosome Clathrin-coated vesicle Cytoplasm Cytoskeleton Endoplasmic reticulum Endosome Extracellular Extracellular matrix Golgi apparatus Integral to membrane Kinetochore Mitochondrion Nucleolus Nucleus Perinuclear region Plasma membrane Ribosome Secreted
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 187 protein expression profiles of 115 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to: 48 different normal tissue types 20 different types of cancer 47 cell lines 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath. BioCarta# 179 Pathways KEGG# 152 Pathways NCI-Nature# 200 Pathways NetPath# 32 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Drug Profile Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms Presentation of drug name and synonyms
Principal Company & Partners Presentation of principal company and partners
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations. Target Expression Profiles Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to: 48 different normal tissue types 20 different types of cancer 47 cell lines 12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status. Example: Cancer, myeloma – Phase II Clinical Trial – Active Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions Analyst comments
Deals & Licensing Collaborations and deals Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available preclinical development data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data.
Application Features Search, Find and Filter Panel with Initial Result Presentation With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources Drug data is linked to search engines like Google and PubMed Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc. Direct links to company web pages of companies
Dynamic Report Generator Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
System Requirements Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online Browser Application (Internet Explorer, Firefox, Chrome, Safari) Internet access (to access related internet resources)
Electronic Access - Global Site License Fulfilled by publisher
Electronic Access - Single User Fulfilled by Publisher